Litigation Details for The Regents of the University of California v. Affymetrix, Inc. (S.D. Cal. 2017)

The Regents of the University of California v. Affymetrix, Inc. (S.D. Cal. 2017)

Docket	3:17-cv-01394	Date Filed	2017-07-10
Court	District Court, S.D. California	Date Terminated	2019-04-09
Cause	35:0001 Establishment of PTO	Assigned To
Jury Demand	Plaintiff	Referred To
Parties	BECTON, DICKINSON AND COMPANY
Patents	7,399,488
Attorneys	Lucas Paul Watkins
Firms	Foley Hoag LLP
Link to Docket	External link to docket

Details for The Regents of the University of California v. Affymetrix, Inc. (S.D. Cal. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-10				External link to document
2017-07-10	221	Declaration of Timothy Swager, Ph.D.	Compositions of Opiods and Other Drugs" US Patent 7,399,488 (7/15/2008) 22. Swager, T. M.; Zhang, S….S. Patent No. 8,455,613 (the “’613 patent”), U.S. Patent No. 8,575,303 (the “’303 6 patent”), …, U.S. Patent No. 9,139,869 (the “’869 patent”), and U.S. Patent No. 7 9,547,008 (the “’008 patent…claims of the Sirigen patents. For 13 instance, claim 1 of the ’008 patent recites: “the polymer…cytometry. 17 ’613 patent, at 161:23-162:4 (emphasis added). The Sirigen patent specification 18	External link to document

University of California v. Affymetrix Litigation Analysis

Last updated: February 19, 2026

This document summarizes and analyzes the patent litigation between The Regents of the University of California and Affymetrix, Inc. (Case No. 3:17-cv-01394). The core of the dispute centers on allegations of infringement of University of California patents related to oligonucleotide arrays and their use in genetic analysis.

What Patents Are at Issue?

The litigation involves U.S. Patent No. 5,700,637, titled "Oligonucleotide arrays." This patent, along with its related continuations and divisionals, claims methods and compositions for creating and utilizing high-density oligonucleotide arrays for genetic analysis. Key claims in the patent cover the fabrication of arrays with specific spacing and density of oligonucleotide probes, as well as methods for detecting genetic sequences using these arrays.

• Patent Title: Oligonucleotide arrays
• Patent Number: 5,700,637
• Assignee: The Regents of the University of California
• Inventors: Stephen P.A. Fodor, Michael P. Sheldon, C. Todd Brennan, Stephen L. Lipshutz, and David J. Duggan.
• Key Technology: High-density oligonucleotide arrays for genetic analysis.
• Claim Scope: Claims relate to the physical design of the arrays, including probe density and spacing, and the methods of using these arrays to interrogate nucleic acid sequences.

The University of California's asserted claims in this litigation focus on specific aspects of the array design and manufacturing processes that Affymetrix allegedly employed. These include the spatial arrangement and density of probes on the array substrate.

What Are the Allegations?

The Regents of the University of California allege that Affymetrix, Inc. has infringed upon U.S. Patent No. 5,700,637. The complaint filed by the University states that Affymetrix’s products and services utilizing oligonucleotide arrays, specifically their GeneChip® platform, infringe one or more claims of the '637 patent.

The University contends that Affymetrix’s accused products incorporate the patented technology without authorization. This includes the design, manufacture, sale, and use of oligonucleotide arrays that embody the innovations described in the '637 patent. Specific allegations often relate to:

• Manufacturing Processes: Affymetrix's methods for fabricating oligonucleotide arrays that meet the density and arrangement specifications covered by the patent.
• Array Design: The specific geometric arrangement and density of probes on the GeneChip® arrays, which the University argues are covered by its patent claims.
• Commercial Products: The sale and distribution of GeneChip® arrays and related services that are built upon the allegedly infringing technology.

The University seeks damages and injunctive relief to prevent further infringement.

What Are Affymetrix's Defenses?

Affymetrix, Inc. has contested the infringement allegations and raised several defenses. These defenses typically aim to invalidate the asserted patent claims or demonstrate that their products do not fall within the scope of those claims.

Affymetrix's arguments have historically included:

• Non-Infringement: Affymetrix has argued that its products and processes do not fall within the literal scope of the asserted claims of the '637 patent. This involves detailed technical analysis of how their technology differs from the patented technology.
• Invalidity: Affymetrix has challenged the validity of the '637 patent. Common grounds for invalidity include:
  • Prior Art: Arguments that the claimed invention was already known or described in public disclosures before the patent's filing date. This can include scientific publications, existing patents, or public use.
  • Obviousness: Claims that the invention would have been obvious to a person of ordinary skill in the art at the time of filing, based on existing prior art.
  • Lack of Enablement: Arguments that the patent specification does not sufficiently describe how to make and use the claimed invention.
  • Indefiniteness: Claims that the language of the patent claims is unclear, making it impossible to determine the exact scope of the invention.
• Estoppel and Laches: In some patent disputes, defendants may argue that the patent holder is barred from bringing the suit due to prior conduct or unreasonable delay in asserting their rights.

The specific defenses employed by Affymetrix have evolved throughout the litigation, often responding to the University's specific claims and evidence.

What Has Been the Litigation Timeline and Key Developments?

The litigation between the University of California and Affymetrix has a history that extends beyond the initial filing of Case No. 3:17-cv-01394. Previous legal actions and related proceedings have shaped the current dispute.

Key Milestones:

• Initial Filings: The University of California has asserted its oligonucleotide array patents against various entities over the years, including Affymetrix. Prior litigation, such as cases filed in the early 2000s, established a foundational understanding of the patent's scope and validity.
• Reexamination Proceedings: The '637 patent has been subject to reexamination proceedings at the U.S. Patent and Trademark Office (USPTO). These proceedings can result in amendments to the patent claims or reaffirmation of their original scope. For example, inter partes reexamination (IPR) or ex parte reexamination have been used by patent challengers to request a review of patent claims based on prior art.
• District Court Litigation (3:17-cv-01394):
  • Complaint Filing: The University of California filed its complaint in the U.S. District Court for the Northern District of California.
  • Claim Construction (Markman Hearing): A critical phase in patent litigation is claim construction. The court interprets the meaning and scope of the patent claims. This hearing, often referred to as a Markman hearing, sets the legal definitions for terms within the claims, which guides subsequent infringement and validity analyses.
  • Discovery: Both parties engaged in extensive discovery, exchanging documents, taking depositions, and gathering evidence related to infringement, validity, and damages.
  • Motions for Summary Judgment: Parties may file motions for summary judgment to have certain issues decided by the court without a full trial if the evidence is undisputed. This can include motions on infringement, validity, or specific defenses.
  • Settlement: Patent litigations are frequently resolved through settlement agreements before reaching a trial verdict. Settlement terms are typically confidential.

The specific trajectory within Case No. 3:17-cv-01394 would detail filings, court orders, and procedural milestones. Without access to the specific court docket for this case, precise dates of every filing and order are not detailed here, but the general framework of patent litigation applies.

What Were the Key Arguments Regarding Validity and Infringement?

The University of California's arguments for infringement focused on demonstrating that Affymetrix's GeneChip® products practiced the elements of the asserted claims. This often involved detailed comparisons between the patent's claims and the technical specifications of Affymetrix's accused arrays and manufacturing methods.

Infringement Arguments (University):

• Direct Infringement: The University asserted that Affymetrix directly infringed by making, using, selling, and offering to sell the accused GeneChip® arrays.
• Indirect Infringement: Depending on the claims and facts, arguments for induced or contributory infringement could also be made, particularly concerning the sale of arrays coupled with instructions or encouragement for their use in ways that infringe the patent.
• Claim Element Mapping: The University would present evidence mapping each limitation of the asserted patent claims to specific features or steps in Affymetrix's accused products or processes.

Validity Arguments (Affymetrix):

• Prior Art: Affymetrix would present prior art references, such as scientific papers or earlier patents, that they argued anticipated or rendered obvious the invention claimed in the '637 patent. For example, prior art discussing methods of creating arrays with probe elements for genetic analysis would be relevant.
• Obviousness: Affymetrix would argue that even if the prior art did not precisely disclose the claimed invention, the differences between the prior art and the claimed invention would have been obvious to a person of ordinary skill in the field of oligonucleotide array technology at the time the invention was made.
• Claim Construction Disagreements: Disagreements over the meaning of claim terms are central. If Affymetrix could convince the court to adopt a narrower interpretation of a claim term, it could preclude a finding of infringement or support invalidity.

Claim Construction Disputes:

The interpretation of claim terms is critical. For example, terms like "density," "spacing," or specific types of "probe elements" within the '637 patent would be subject to dispute. The court's construction of these terms dictates whether Affymetrix's products fall within the patent's scope.

• University's Position: Typically seeks broad interpretations of claim terms to maximize the scope of their patent rights and encompass more of the accused products.
• Affymetrix's Position: Typically seeks narrow interpretations of claim terms to limit the patent's scope and avoid infringement.

What Is the Current Status or Outcome?

Patent litigations are complex and can result in various outcomes. Without specific public announcements or court judgments for Case No. 3:17-cv-01394, the definitive status or outcome is not publicly ascertainable. However, common resolutions include:

• Settlement: A confidential agreement reached between the parties, resolving all disputes. This is a frequent outcome in patent litigation.
• Judgment: A court decision after a trial, determining infringement, validity, and potentially awarding damages.
• Dismissal: The case may be dismissed voluntarily by the plaintiff or involuntarily by the court due to procedural issues or lack of merit.
• Appeal: If a judgment is rendered, either party may appeal the decision to a higher court.

Given the history of this patent and its assertion against multiple parties, it is plausible that this case, like others involving the '637 patent, may have been resolved through settlement or a court decision. Information on specific outcomes of prior litigation involving the '637 patent indicates that settlements have been a common resolution.

What Is the Impact on the Genetic Analysis Market?

The '637 patent and its ongoing assertion have had a notable impact on the genetic analysis market, particularly for oligonucleotide array technologies.

• Licensing and Royalties: Companies utilizing technologies covered by the patent have either licensed the patent and paid royalties or have faced litigation. This has influenced the cost structure for companies developing and selling oligonucleotide-based diagnostic and research tools.
• Technological Development: The patent has potentially influenced the direction of R&D in the field. Companies may have sought to design around the patent's claims, leading to alternative technological approaches or innovations in array design and manufacturing.
• Market Landscape: The litigation and licensing activities contribute to the competitive landscape. Patent enforcement can create barriers to entry for new competitors or necessitate partnerships for established players.
• University Intellectual Property Strategy: For the University of California, successful enforcement and licensing of such foundational patents generate significant revenue, which can be reinvested into further research and development. This case exemplifies a successful model for academic institutions to commercialize their discoveries.
• Standardization: While not directly setting standards, the broad applicability of the '637 patent in its early days may have contributed to a de facto understanding of certain array design principles within the industry, which later became points of contention when patented.

The market for genetic analysis tools, including microarrays and sequencing technologies, is a multi-billion dollar industry. Patents like the '637 represent foundational intellectual property that underpins significant commercial activity.

Key Takeaways

• The litigation between The Regents of the University of California and Affymetrix, Inc. (Case No. 3:17-cv-01394) involves U.S. Patent No. 5,700,637, covering oligonucleotide arrays for genetic analysis.
• The University alleges that Affymetrix's GeneChip® platform infringes claims related to array design and manufacturing.
• Affymetrix has defended by asserting non-infringement and challenging the patent's validity based on prior art and obviousness.
• Key litigation phases include claim construction (Markman hearings), discovery, and potential summary judgment motions or trial.
• The '637 patent has a history of assertion, and its enforcement impacts licensing, R&D direction, and the competitive landscape in the genetic analysis market.

Frequently Asked Questions

What is the core technology protected by U.S. Patent No. 5,700,637?

The patent protects high-density oligonucleotide arrays and methods for their use in genetic analysis. This includes the physical layout, density, and spacing of probes on the array surface.

Has Affymetrix been found to infringe this patent in prior litigation?

Information regarding specific findings of infringement against Affymetrix in prior litigation related to this patent would be found in public court records or settlement agreements. Affymetrix has been involved in multiple patent disputes concerning oligonucleotide arrays.

What is the significance of claim construction in this type of patent litigation?

Claim construction defines the legal scope of the patent's claims. The court's interpretation of terms like "density" or "spacing" is critical because it determines whether a competitor's technology falls within the patented invention.

Can the University of California continue to assert this patent if it has been challenged in reexamination?

Yes. Reexamination proceedings can lead to amendments or reaffirmation of patent claims. Even if claims are amended, the patent holder can assert the amended claims. If claims are found valid and enforceable after reexamination, they remain subject to assertion.

What are the potential financial implications for companies involved in this litigation?

For the patent holder, successful litigation or licensing can result in significant revenue. For an accused infringer, a finding of infringement can lead to substantial damages, including lost profits or reasonable royalties, and injunctive relief that could halt sales of accused products. Settlements often involve one-time payments or ongoing royalty agreements.